Developer docs
API playgroundTry for free, no card

Search company profiles

Main Sequence Ventures

Full company profile

uuid000061g

Namestring
Main Sequence Ventures
Legal namestring
Main Sequence Ventures
Websiteurl
mseq.vc
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Main Sequence Ventures is an Australian deep tech venture capital firm co-founded by CSIRO in 2017 and headquartered in Sydney. The firm invests venture capital from pre-seed through Series B in spinouts, startups, and SMEs connected to Australian publicly funded research, organised around six challenge areas: Bridge the Gap to Space, Decarbonise the Planet, Enable the Next Intelligence Leap, Feed 10 Billion People, Reach Humanity Scale Healthcare, and Supercharge Industrial Productivity. Main Sequence's core differentiator is its exclusive structural relationship with CSIRO, Australia's national science agency, which provides portfolio companies with access to 3,500 scientists, prototyping and testing infrastructure, Australia's largest patent portfolio, and relationships with all 43 Australian universities.

The firm operates a multi-stage platform that includes the Atmosphere pre-seed programme, the core seed-to-Series B investment vehicle, and the Spin-out Series research commercialisation programme, all underpinned by the proprietary "Venture Science" methodology and downloadable Toolkit. Main Sequence has raised three funds — Fund 1 ($240M, 2017), Fund 2 ($310M, private capital), and Fund 3 ($450M, 2023) — bringing total funds under management above $1B, with Fund 4 expected to launch late 2026 / early 2027. Across Funds 1 and 2 the firm has invested in 51 portfolio companies; Fund 3 has made 16 investments to date.

Main Sequence generates returns for LPs (institutional investors, superannuation funds, family offices, and the Australian government as cornerstone investor) through portfolio company exits and secondary transactions, earning management fees and carried interest on returns above the preferred return threshold. The firm does not sell products or services to end customers and does not publicly disclose fee rates. Distribution to founders occurs through direct outreach, researcher office hours, the Atmosphere pre-seed programme, and CSIRO ecosystem relationships; LPs are engaged through direct wholesale fundraising, with a global co-investor network supporting portfolio company international scaling.

Short descriptiontext

Main Sequence Ventures is an Australian deep tech venture capital firm, founded by CSIRO in 2017, that invests from pre-seed through Series B in startups connected to Australian publicly funded research across six challenge areas, managing over $1B across three funds.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
deep tech venture capital, research commercialisation funding, pre-seed venture funding, frontier technology investing, startup equity investment
Industry2 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1VC Fund Management & Carried Interest
TypeSubscription Recurring
Description

Main Sequence generates returns for Limited Partners (institutional investors, superannuation funds, family offices) by investing in deep tech startups and realizing returns through portfolio company exits (IPOs, acquisitions) and secondary transactions. The firm earns management fees and carried interest on returns above the preferred return threshold.

mseq.vc
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Main Sequence Ventures is an Australian deep tech venture capital firm that invests equity capital from pre-seed through Series B into startups connected to Australian publicly funded research. The firm manages over $1 billion across multiple funds and provides portfolio companies with hands-on company-building support, including access to CSIRO scientists, prototyping infrastructure, and proprietary Venture Science methodology tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Main Sequence surpassed $1 billion in funds under management, making it one of Australia's largest deep tech VC firms
+3 more records
Product overview1 text field

Main Sequence Ventures is a deep tech venture capital firm designed to support founders building difficult-to-build companies. The firm offers a unified investment platform with multiple funding stages: the Atmosphere pre-seed program for earliest-stage founders, core venture investment from seed through Series B, and research commercialisation support through Spin-out Series resources. The Venture Science Toolkit provides methodological framework for company building. The firm's investment thesis is organized around six global challenges: Bridge the Gap to Space, Decarbonise the Planet, Enable the Next Intelligence Leap, Feed 10 Billion People, Reach Humanity Scale Healthcare, and Supercharge Industrial Productivity. Main Sequence leverages its unique partnership with CSIRO, Australia's national science agency, to provide portfolio companies with access to infrastructure, scientists, and testing facilities.

Product and service4 records
1Deep Tech Venture Capital Investment
Categorycore venture investment
2Atmosphere Pre-seed Fund
Categorypre-seed venture program
3Spin-out Series
Categoryresearch commercialisation support
4Researcher Office Hours
Categoryresearch commercialisation support
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1CSIRO (Commonwealth Scientific and Industrial Research Organisation)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

CSIRO, Australia's national science agency with a $1.3 billion annual budget, co-founded Main Sequence in 2017 to bridge the valley of death for research commercialisation. CSIRO is Main Sequence's anchor limited partner and provides portfolio companies with access to 3,500 scientists, infrastructure, Australia's largest patent portfolio, prototyping facilities, and testing & certification capabilities. Economic returns from commercialisation are reinvested back into science.

mseq.vc
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Aerospace and defence company partnered with Cortisonic through the Australian Department of Defence's Advanced Strategic Capabilities Accelerator programme to demonstrate Cortisonic's phononic computing technology within 24 months.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Listed technology and life sciences commercialization company that invests in university and research institute spinouts. Highly comparable to Main Sequence's deep tech commercialization model, with explicit focus on Australian publicly funded research and a co-investor in Main Sequence's portfolio companies.

2Uniseed
TypeDirect peer
Description

Australian university commercialization fund that invests in early-stage spinouts from partner research institutions. Directly comparable to Main Sequence's pre-seed and seed activity through Atmosphere, focusing on commercializing Australian academic research.

TypeBroad incumbent
Description

One of Australia's largest and most established venture capital firms, leading investments across technology stages. Overlaps with Main Sequence as a co-investor (notably Gilmour Space's Series E) but operates broadly rather than specializing in deep tech spinouts from publicly funded research.

TypeBroad incumbent
Description

Major Australian venture capital firm with a diversified portfolio spanning consumer, enterprise, and deep tech. Comparable as a co-investor in Main Sequence portfolio companies (Advanced Navigation Series C), but with a broader investment remit beyond research commercialization.

TypeBroad incumbent
Description

Australia and Israel-focused venture capital firm investing across technology stages. Comparable as a fellow Australian deep tech investor, though with broader geographic and sector scope than Main Sequence's publicly-funded-research mandate.

TypeDirect peer
Description

Australian life sciences venture capital firm managing the Medical Research Commercialisation Fund (MRCF) and Biomedical Translation Fund (BTF). Highly comparable deep tech commercialization model anchored to Australian publicly funded research and medical research institutes.

TypeRegional player
Description

Australian and New Zealand venture capital firm investing across early-stage technology companies. Comparable as an Australia-focused early-stage VC and co-investor in Main Sequence portfolio companies (Arkeus Series A), though not deep tech or research-spinout specialized.

TypeEmerging player
Description

US-based venture capital firm specializing in deep tech investments across AI, space, healthcare, and advanced materials. Comparable as a deep tech specialist, though US-headquartered with access to American research institutions rather than Australian publicly funded research.

TypeEmerging player
Description

US-based venture capital firm investing in deep tech companies using computational, engineering, and materials science breakthroughs. Comparable as a deep tech specialist with science-driven thesis, though serving American rather than Australian research commercialization.

TypeBroad incumbent
Description

Bill Gates-backed global venture fund investing in climate and deep tech companies across energy, agriculture, and industrial sectors. Comparable as a deep tech and decarbonization investor aligned with Main Sequence's 'Decarbonise the Planet' challenge area, though with global mandate rather than Australian focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment128 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Main Sequence Ventures

Venture Capitalmseq.vc

Main Sequence Ventures is an Australian deep tech venture capital firm, founded by CSIRO in 2017, that invests from pre-seed through Series B in startups connected to Australian publicly funded research across six challenge areas, managing over $1B across three funds.

What Main Sequence Ventures does

Main Sequence Ventures is an Australian deep tech venture capital firm co-founded by CSIRO in 2017 and headquartered in Sydney. The firm invests venture capital from pre-seed through Series B in spinouts, startups, and SMEs connected to Australian publicly funded research, organised around six challenge areas: Bridge the Gap to Space, Decarbonise the Planet, Enable the Next Intelligence Leap, Feed 10 Billion People, Reach Humanity Scale Healthcare, and Supercharge Industrial Productivity. Main Sequence's core differentiator is its exclusive structural relationship with CSIRO, Australia's national science agency, which provides portfolio companies with access to 3,500 scientists, prototyping and testing infrastructure, Australia's largest patent portfolio, and relationships with all 43 Australian universities.

The firm operates a multi-stage platform that includes the Atmosphere pre-seed programme, the core seed-to-Series B investment vehicle, and the Spin-out Series research commercialisation programme, all underpinned by the proprietary "Venture Science" methodology and downloadable Toolkit. Main Sequence has raised three funds — Fund 1 ($240M, 2017), Fund 2 ($310M, private capital), and Fund 3 ($450M, 2023) — bringing total funds under management above $1B, with Fund 4 expected to launch late 2026 / early 2027. Across Funds 1 and 2 the firm has invested in 51 portfolio companies; Fund 3 has made 16 investments to date.

Main Sequence generates returns for LPs (institutional investors, superannuation funds, family offices, and the Australian government as cornerstone investor) through portfolio company exits and secondary transactions, earning management fees and carried interest on returns above the preferred return threshold. The firm does not sell products or services to end customers and does not publicly disclose fee rates. Distribution to founders occurs through direct outreach, researcher office hours, the Atmosphere pre-seed programme, and CSIRO ecosystem relationships; LPs are engaged through direct wholesale fundraising, with a global co-investor network supporting portfolio company international scaling.

Main Sequence Ventures firmographics

Firmographics
Name
Main Sequence Ventures
Legal name
Main Sequence Ventures
Website
https://mseq.vc
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Main Sequence Ventures is an Australian deep tech venture capital firm, founded by CSIRO in 2017, that invests from pre-seed through Series B in startups connected to Australian publicly funded research across six challenge areas, managing over $1B across three funds.
Ownership category
akta.pro rank

Main Sequence Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Deep tech venture capital
  • Research commercialisation funding
  • Pre-seed venture funding
  • Frontier technology investing
  • Startup equity investment

Where Main Sequence Ventures is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Main Sequence Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. VC Fund Management & Carried Interest: Main Sequence generates returns for Limited Partners (institutional investors, superannuation funds, family offices) by investing in deep tech startups and realizing returns through portfolio company exits (IPOs, acquisitions) and secondary transactions. The firm earns management fees and carried interest on returns above the preferred return threshold.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Main Sequence Ventures product offering

Product offering

Core offering

Main Sequence Ventures is an Australian deep tech venture capital firm that invests equity capital from pre-seed through Series B into startups connected to Australian publicly funded research. The firm manages over $1 billion across multiple funds and provides portfolio companies with hands-on company-building support, including access to CSIRO scientists, prototyping infrastructure, and proprietary Venture Science methodology tools.

Product overview

Main Sequence Ventures is a deep tech venture capital firm designed to support founders building difficult-to-build companies. The firm offers a unified investment platform with multiple funding stages: the Atmosphere pre-seed program for earliest-stage founders, core venture investment from seed through Series B, and research commercialisation support through Spin-out Series resources. The Venture Science Toolkit provides methodological framework for company building. The firm's investment thesis is organized around six global challenges: Bridge the Gap to Space, Decarbonise the Planet, Enable the Next Intelligence Leap, Feed 10 Billion People, Reach Humanity Scale Healthcare, and Supercharge Industrial Productivity. Main Sequence leverages its unique partnership with CSIRO, Australia's national science agency, to provide portfolio companies with access to infrastructure, scientists, and testing facilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Deep Tech Venture Capital Investment
  • Atmosphere Pre-seed Fund
  • Spin-out Series
  • Researcher Office Hours

Quantifiable outcome

  • Main Sequence surpassed $1 billion in funds under management, making it one of Australia's largest deep tech VC firms
  • +3 more outcomes

Companies that use Main Sequence Ventures

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Main Sequence Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Main Sequence Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and supporting.

  • CSIRO (Commonwealth Scientific and Industrial Research Organisation)coreStrategic or Co-development Partner · 1 January 2017CSIRO, Australia's national science agency with a $1.3 billion annual budget, co-founded Main Sequence in 2017 to bridge the valley of death for research commercialisation. CSIRO is Main Sequence's anchor limited partner and provides portfolio companies with access to 3,500 scientists, infrastructure, Australia's largest patent portfolio, prototyping facilities, and testing & certification capabilities. Economic returns from commercialisation are reinvested back into science.
  • Lockheed Martin AustraliasupportingStrategic or Co-development PartnerAerospace and defence company partnered with Cortisonic through the Australian Department of Defence's Advanced Strategic Capabilities Accelerator programme to demonstrate Cortisonic's phononic computing technology within 24 months.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Main Sequence Ventures competitors and assessment

Company assessment

Direct peers

  • IP Group Australia: Listed technology and life sciences commercialization company that invests in university and research institute spinouts. Highly comparable to Main Sequence's deep tech commercialization model, with explicit focus on Australian publicly funded research and a co-investor in Main Sequence's portfolio companies.
  • Uniseed: Australian university commercialization fund that invests in early-stage spinouts from partner research institutions. Directly comparable to Main Sequence's pre-seed and seed activity through Atmosphere, focusing on commercializing Australian academic research.
  • Brandon Capital: Australian life sciences venture capital firm managing the Medical Research Commercialisation Fund (MRCF) and Biomedical Translation Fund (BTF). Highly comparable deep tech commercialization model anchored to Australian publicly funded research and medical research institutes.

Broad incumbents

  • Blackbird Ventures: One of Australia's largest and most established venture capital firms, leading investments across technology stages. Overlaps with Main Sequence as a co-investor (notably Gilmour Space's Series E) but operates broadly rather than specializing in deep tech spinouts from publicly funded research.
  • AirTree Ventures: Major Australian venture capital firm with a diversified portfolio spanning consumer, enterprise, and deep tech. Comparable as a co-investor in Main Sequence portfolio companies (Advanced Navigation Series C), but with a broader investment remit beyond research commercialization.
  • Square Peg Capital: Australia and Israel-focused venture capital firm investing across technology stages. Comparable as a fellow Australian deep tech investor, though with broader geographic and sector scope than Main Sequence's publicly-funded-research mandate.
  • Breakthrough Energy Ventures: Bill Gates-backed global venture fund investing in climate and deep tech companies across energy, agriculture, and industrial sectors. Comparable as a deep tech and decarbonization investor aligned with Main Sequence's 'Decarbonise the Planet' challenge area, though with global mandate rather than Australian focus.

Regional players

  • Folklore Ventures: Australian and New Zealand venture capital firm investing across early-stage technology companies. Comparable as an Australia-focused early-stage VC and co-investor in Main Sequence portfolio companies (Arkeus Series A), though not deep tech or research-spinout specialized.

Emerging players

  • Lux Capital: US-based venture capital firm specializing in deep tech investments across AI, space, healthcare, and advanced materials. Comparable as a deep tech specialist, though US-headquartered with access to American research institutions rather than Australian publicly funded research.
  • DCVC (Data Collective): US-based venture capital firm investing in deep tech companies using computational, engineering, and materials science breakthroughs. Comparable as a deep tech specialist with science-driven thesis, though serving American rather than Australian research commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Main Sequence Ventures social profiles

Digital presence

Main Sequence Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Main Sequence Ventures leadership team

Management profile

Number of profiles

Profiles24 records

Main Sequence Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Main Sequence Ventures M&A and investment

M&A and investment

M&A

Investments128 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Main Sequence Ventures

What does Main Sequence Ventures do?

Main Sequence Ventures is an Australian deep tech venture capital firm that invests equity capital from pre-seed through Series B into startups connected to Australian publicly funded research. The firm manages over $1 billion across multiple funds and provides portfolio companies with hands-on company-building support, including access to CSIRO scientists, prototyping infrastructure, and proprietary Venture Science methodology tools.

Is Main Sequence Ventures a public or private company?

Main Sequence Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Main Sequence Ventures founded?

Main Sequence Ventures was founded in 2017. It employs 11 to 50 people.

Where is Main Sequence Ventures based?

Main Sequence Ventures is headquartered in Sydney, Australia, in the Oceania region.

How does Main Sequence Ventures make money?

One revenue line is on record: VC Fund Management & Carried Interest.

Who are Main Sequence Ventures's main competitors?

Direct peers on record are IP Group Australia, Uniseed and Brandon Capital. Broad incumbents are Blackbird Ventures, AirTree Ventures, Square Peg Capital and Breakthrough Energy Ventures. Folklore Ventures is listed as a regional player. Emerging players are Lux Capital and DCVC (Data Collective).

Does Main Sequence Ventures have an API?

No public API is recorded for Main Sequence Ventures.

What industry is Main Sequence Ventures in?

Main Sequence Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup ResearcherMain Sequence Promotes Elaine Stead to Partner Ahead of Fund 4Main Sequence promoted Dr. Elaine Stead from Principal to Partner ahead of its fourth fund, with a first close planned before year-end. Stead has led the firm's healthcare strategy since March 2024, and the promotion reflects leadership expansion. The firm is actively in market for Fund 4.The SaaS NewsMetacognition Raises $10M Pre-seedMetacognition, an Australian AI startup, raised $10 million in a pre-seed round led by Main Sequence. The company will use the funds to scale its headcount from about 10 to 100 employees and develop AI software layers for mining and enterprise operations.Startup DailyAI startup raises $10 million to build robotics operating systemMetacognition AI raised $10 million from CSIRO-backed VC Main Sequence to build a robotics operating system. The startup aims to enable non-experts to train robots via simple verbal instructions, targeting existing industrial systems. Its team of eight is expanding with AI researcher hires.Forbes AustraliaAustralian AI lab caps $10 million pre-seed raise to run in global AI raceMetacognition raised $10 million in pre-seed funding from Main Sequence, ten times Australia's pre-seed average. The AI lab builds reasoning and memory layers to prevent unsafe AI behavior, targeting enterprise applications like mining. It plans to raise more capital to compete with US firms.Startup DailyHow former theatre director Phil Morle became a startup visionaryPhil Morle, a cofounder of CSIRO-backed Main Sequence Ventures, discusses his approach to investing in deep-tech startups by emphasizing the transition from narrative excitement to tangible investor conviction. He illustrates this strategy through examples such as Samsara Eco's partnership with Lululemon, which serves as proof of commitment beyond mere promotional value. The article highlights how securing partners who co-invest in a vision helps validate unproven technologies for other stakeholders.iTWireMain Sequence promotes Alejandra Romero to Principal for advanced compute eraMain Sequence Ventures, Australia's deep tech venture capital firm, has promoted Alejandra Romero to Principal, reflecting the firm's strategic emphasis on hardware-level computing advantages across semiconductors, quantum computing, and AI hardware. Romero leads the firm's advanced physical systems investment thesis and has backed portfolio companies including Q-CTRL, Diraq, and Quantum Brilliance, having previously helped commercialize university technology through Cortisonic with Lockheed Martin as its first commercial partner. She has progressed from Investment Analyst to Principal since joining Main Sequence in 2023, working closely with CSIRO and Australian research institutions.Forbes AustraliaThis drone startup bagged BHP, Rio Tinto as customers. Now it’s raised $25m to tackle defence spending boomCSIRO-spinout Emesent has raised $25 million in funding, including $10 million in venture debt from the Australian Government's National Reconstruction Fund, with participation from superannuation funds Hostplus, NGS Super, and investors including Main Sequence, QIC Ventures, and Orion Resource Partners. The drone tech startup, which has historically served mining customers BHP and Rio Tinto with GPS-denied surveying sensors, is using the capital to boost manufacturing capacity at its Wacol, Queensland plant and expand into the defence sector, adding 20 roles to its current team of 109. The NRF's $10 million venture debt commitment marks its first foray into venture debt, a funding mechanism the fund aims to grow in Australia as it seeks to bolster sovereign advanced manufacturing capability.Maritime NewsAustralian Quantum Sensor Company Raises Seed FundingDeteqt, an Australian quantum sensor company, closed a A$5 million seed round led by Main Sequence. The company builds chip-scale quantum magnetometers for GPS-denied navigation, with applications in marine and subsea environments. The funding will advance field-ready prototypes toward commercial deployment.Marine Technology NewsAustralian Quantum Sensor Company Raises Seed FundingDeteqt, an Australian deep tech company, closed a A$5 million seed round led by Main Sequence. The company builds chip-scale quantum magnetometers for GPS-denied navigation, with applications in marine and subsea environments. The funding will advance field-ready sensors toward commercial deployments.The SaaS NewsArkeus Raises $18 Million Series AArkeus, a Melbourne-based defense technology company, raised $18 million in Series A funding led by QIC Ventures. The company will use the funds to accelerate global expansion, scale manufacturing, and develop AI-powered hyperspectral sensing systems for autonomous military platforms.